Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 61 to 75 of 187 results for prostate cancer

  1. Catumaxomab for intraperitoneal treatment of malignant ascites in epithelial cellular adhesion molecule-positive carcinomas when further systemic anticancer treatment is unsuitable [ID6580]

    In development Reference number: GID-TA11774 Expected publication date:  30 September 2026

    Technology appraisal guidance
    In development

  2. Staging investigations for CPG 3 prostate cancer: What is the diagnostic accuracy of staging investigations for CPG 3 prostate cancer?

    investigations for CPG 3 prostate cancer: What is the diagnostic accuracy of staging investigations for CPG 3 prostate...

    Research recommendation
    Published
    7 January 2022

  3. What is the most clinically and cost-effective pathway for diagnosing clinically significant prostate cancer?

    clinically and cost-effective pathway for diagnosing clinically significant prostate cancer? Any explanatory notes(if applicable) Why...

    Research recommendation
    Published
    25 October 2019

  4. What is the most clinically and cost-effective pathway for diagnosing clinically significant prostate cancer?

    clinically and cost-effective pathway for diagnosing clinically significant prostate cancer? Any explanatory notes(if applicable) Why...

    Research recommendation
    Published
    7 January 2022

  5. Past appeals and decisions

    Past technology appraisal appeals and decisions

  6. GreenLight XPS for treating benign prostatic hyperplasia (HTG650)

    Evidence-based recommendations on GreenLight XPS for treating benign prostatic hyperplasia.

    HealthTech guidance
    Published
    29 November 2022
    View recommendations

    Sections for HTG650

  7. Brachytherapy as the sole method of adjuvant radiotherapy for breast cancer after local excision (HTG171)

    Evidence-based recommendations on brachytherapy as the sole method of adjuvant radiotherapy for breast cancer after local excision. This involves inserting radioactive sources into the space in the breast where tissue has been removed to minimise the chances of the cancer coming back.

    HealthTech guidance
    Published
    23 July 2008
    View recommendations

    Sections for HTG171

  8. In patients with negative MRI (Likert score 1 or 2), what is the next best diagnostic investigation to rule out clinically significant prostate cancer? What is the diagnostic accuracy of transperineal mapping biopsy compared with transperineal non-mapping biopsy in the diagnosis of clinically significant prostate cancer?

    next best diagnostic investigation to rule out clinically significant prostate cancer? What is the diagnostic accuracy of transperineal...

    Research recommendation
    Published
    25 October 2019

  9. What is the prognostic value of different risk stratification methods for people with locally advanced prostate cancer?

    advanced prostate cancer? Any explanatory notes(if applicable) Source guidance details Comes from guidance Prostate cancer:...

    Research recommendation
    Published
    25 October 2019

  10. Lower urinary tract symptoms in men (QS45)

    This quality standard covers diagnosing and managing lower urinary tract symptoms in men (aged 18 and over). It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    18 September 2013
    View quality statements

    Sections for QS45

  11. Clinicians should collect data on all patients undergoing focal cryoablation (including details of case selection, methods of follow-up and outcomes) for local audit. Clinicians should enter details about all patients undergoing focal therapy using cryoablation for localised prostate cancer onto the European Registry for Cryosurgical Ablation of the Prostate (EuCAP) register and review clinical outcomes locally.

    using cryoablation for localised prostate cancer onto the European Registry for Cryosurgical Ablation of the Prostate...

    Research recommendation
    Published
    9 June 2015

  12. Osteoporosis: assessing the risk of fragility fracture (CG146)

    This guideline covers assessing the risk of fragility fracture in people aged 18 and over with osteoporosis. It aims to provide guidance on the selection and use of risk assessment tools in the care of adults at risk of fragility fractures in all NHS settings.

    Clinical guideline
    Last updated
    7 February 2017
    View recommendations

    Sections for CG146

  13. What is the effectiveness and cost effectiveness of different scheduling of zoledronic acid in the prevention and reduction of skeletal events in people with hormone-refractory prostate cancer?

    hormone-refractory prostate cancer? Any explanatory notes(if applicable) Source guidance details Comes from guidance Prostate...

    Research recommendation
    Published
    25 October 2019

  14. NICE considered that if enzalutamide is used in routine clinical practice for treating hormone relapsed metastatic prostate cancer that has been previously treated with abiraterone, data should be collected on resource use and overall survival.

    routine clinical practice for treating hormone relapsed metastatic prostate cancer that has been previously treated with abiraterone,...

    Research recommendation
    Published
    9 June 2015

  15. Cancers insufficiently researched in primary care: Observational studies of symptomatic primary care patients should be used to estimate the positive predictive value of different symptoms for specific cancers. Priority areas for research are those where the evidence base is currently insufficient and should include prostate cancer, pancreatic cancer, cancer in childhood and young people and other rare cancers. Outcomes of interest are positive predictive values and likelihood ratios for cancer.

    Recommendation ID NG131/03 Question Cancers insufficiently researched in primary care: Observational studies of symptomatic primary care

    Research recommendation
    Published
    7 January 2022